A5078270995- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Rheumatoid Arthritis Research and Therapies
- Long-Term Effects of COVID-19
- Autoimmune and Inflammatory Disorders Research
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Polyomavirus and related diseases
- Systemic Lupus Erythematosus Research
- Prion Diseases and Protein Misfolding
- SARS-CoV-2 and COVID-19 Research
- Advanced MRI Techniques and Applications
- Autoimmune Neurological Disorders and Treatments
- Systemic Sclerosis and Related Diseases
- Family Support in Illness
- Research on Leishmaniasis Studies
- Protease and Inhibitor Mechanisms
- Climate Change and Health Impacts
- Elasticity and Material Modeling
- COVID-19 Clinical Research Studies
- Cerebral Palsy and Movement Disorders
- Ultrasound Imaging and Elastography
- Parkinson's Disease Mechanisms and Treatments
- Cerebral Venous Sinus Thrombosis
- Multiple Myeloma Research and Treatments
- Plant Virus Research Studies
Jacobs Institute
2018-2025
University at Buffalo, State University of New York
2018-2025
Jacobs (United States)
2019-2024
Cognitive impairment is common in multiple sclerosis (MS) but its manifestation as acute disease activity underappreciated.The aim of this study to examine recovery after MS relapse on tests cognitive and motor function explore correlates change with Expanded Disability Status Scale (EDSS), magnetic resonance imaging (MRI), reserve.Fifty relapsing group (RG) matched stable participants were examined at baseline, during relapse, 3-month follow-up. Tests processing speed (Symbol Digit...
Background: To determine the effect of disease-modifying therapies (DMT) on humoral postvaccine seroconversion, long-term response, and breakthrough COVID-19 infections in persons with multiple sclerosis (PwMS) other neuroinflammatory disorders. Methods: A total 757 PwMS disorders were recruited two MS centers vaccinated one FDA-approved vaccines (BNT162b2, mRNA-1273, Ad26.COV2.S). The primary outcomes are rate seroconversion anti-severe acute respiratory syndrome coronavirus 2...
Persons with neuroinflammatory diseases (pwNID) treated potent immunosuppressives are at risk of severe COVID-19 outcomes and reduced vaccine seroconversion. We aimed determining the real-world efficacy tixagevimab cilgavimab (Evusheld™) in immunosuppressed pwNID preventing breakthrough infections.31 were followed for 6 months after administration as a prophylactic medication (January 2022-July 2022). Only anti-CD20 monoclonal antibodies sphingosine-1-phosphate modulators considered eligible...
CE INFORMATION ACTIVITY AVAILABLE ONLINE: To access the article and evaluation online, go to https://www.highmarksce.com/mscare. TARGET AUDIENCE: The target audience for this activity is physicians, advanced practice clinicians, nursing professionals, mental health social workers, other care providers involved in management of patients with multiple sclerosis (MS). LEARNING OBJECTIVE: Evaluate how personality traits caregiver characteristics influence quality life burden levels identify MS...
Abstract Objective Baseline paramagnetic rim lesion (PRL) load predicts disease progression in people with multiple sclerosis (pwMS). Understanding how PRLs relate to other known MS‐related factors, and the practical utility of clinical trials, is crucial for informing decision‐making guiding development novel disease‐modifying treatments (DMTs). Methods This study included 152 pwMS enrolled a larger prospective, longitudinal cohort who had 3T MRI scans assessments at baseline 5‐ or 10‐year...
Cognitive impairment is common in multiple sclerosis and negatively impacts quality of life. status has yet to be described people with severe progressive sclerosis, whom conventional neuropsychological testing exceptionally difficult. The objective for the study was characterize cognitive performance compare them age-, sex- disease duration-matched less disabled using a specifically developed auditory, non-motor test attention/cognitive processing speed-Auditory Test Processing Speed. Also,...
The existing reports regarding the potential role of infections as well antibiotic use in multiple sclerosis (MS) etiology are inconclusive.We aimed to investigate association viral and risk developing MS.This was a population-based incident case-control study 547 cases 1057 general population controls obtained from 22 municipality areas Tehran (7/8/2013-17/2/2015). Multiple logistic regression models were used determine adjusted associations.Overall for ≥14 days during 3 years before index...
<h3>BACKGROUND AND PURPOSE:</h3> It is unknown whether deceleration of brain atrophy associated with disability improvement in patients MS. Our aim was to investigate MS develop less compared those who progress or remain stable. <h3>MATERIALS METHODS:</h3> We followed 980 for a mean 4.8 ± 2.4 years. Subjects were divided into 3 groups: (<i>n</i> = 241, 24.6%), 101, 10.3%), and stable 638, 65.1%) at follow-up. Disability defined on the basis Expanded Status Scale score change using...
Introduction The etiology of multiple sclerosis (MS) remains unknown. Pathogenesis likely relies on a complex interaction between environmental, genetic, and behavioral risk factors. However, growing body literature supports the role preceding Epstein-Barr virus (EBV) infection in majority cases.
Disease-modifying therapies (DMTs) can alter multiple sclerosis (MS) disease course. Peak prevalence age for people with MS (pwMS) has increased, but little is known about clinical course or DMT response in older pwMS. The objective of this retrospective analysis a US administrative claims database to was evaluate course, use, healthcare utilisation, and time relapse during follow-up, pwMS ≥50 years active disease. Inclusion criteria were ≥3 years' continuous enrolment, ≥1 (index event),...
Objective: To describe the clinical outcome of four MS patients who developed PML while on natalizumab treated with CDV or CMX001. Background: Progressive-multifocal encephalopathy (PML) is a viral brain infection caused by JC polyomavirus (JCV) which often fatal. Case reports beneficial outcomes in treatment cidofovir combined mirtazapine some immunocompromised patients, but to date, no publications for associated multiple sclerosis (MS) therapy such as natalizumab. CMX001 (Brincidofovir),...
Background and Objective: Pregnancy in mothers with multiple sclerosis (MS) commonly results significant changes disease activity clinical care, including the discontinuation of modifying therapy (DMT). This study aimed at understanding patient-reported outcomes (PROs) before, during 1-year after delivery. Materials Methods: A total 30 pregnant MS were recruited as part study. Clinical (relapse disability changes), PRO information MRI collected on four separate visits: one baseline...